HomeAI · summaries
Storia in 2 fonti
Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win
Merck's tulisokibart hits Phase 3 primary endpoint in ulcerative colitis, a first win for anti-TL1A drugs and the $10.8B Prometheus deal.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win
Merck's tulisokibart hits Phase 3 primary endpoint in ulcerative colitis, a first win for anti-TL1A drugs and the $10.8B Prometheus deal.
- ·
benzinga.com
Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy - Merck & Co (NYSE:MRK)
Merck reported positive Phase 3 data for tulisokibart in ulcerative colitis, meeting primary and key secondary endpoints.